Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins

Biological Chemistry

Volumn 384, Issue 8, 2003, Pages 1119-1131

  Reuning, Ute ^a   Magdolen, Viktor ^a   Hapke, Sandra ^a   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cell adhesion; Cell migration; Extracellular matrix; Integrins; Urokinase type plasminogen activator

Indexed keywords

BINDING PROTEIN; CELL RECEPTOR; INTEGRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

CELL ACTIVITY; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; EXTRACELLULAR MATRIX; HUMAN; MICROENVIRONMENT; MODULATION; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION; CELL MOVEMENT; HUMANS; INTEGRINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 0141738665     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2003.125     Document Type: Review

References (108)

1. Adachi, Y., Lakka, S. S., Chandrasekar, N., Yanamandra, N., Gondi, C. S., Mohanam, S., Dinh, D. H., Olivero, W. C., Gujrati, M., Tamiya, T. et al. (2001). Down-regulation of integrin αvβ3 expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPA-R) and sense p16 genes. J. Biol. Chem. 276, 47171-47177.
2. Ahmed, N., Pansino, F., Clyde, R., Murthi, P., Quinn, M. A., Rice, G. E., Agrez, M. V., Mok, S., and Baker, M. S. (2002). Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 23, 237-244.
3. Al-Fakhri, N., Chavakis, T., Schmidt-Wöll, T., Huang, B., Cherian, S. M., Bobryshev, Y. V., Lord, R. S. A., Katz, N., and Preissner, K. T. (2003). Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol. Chem. 384, 423-435.
4. Andreasen, P. A., Egelund, R., and Petersen, H. H. (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57, 25-40.
5. Arroyo De Prada, N., Schroeck, F., Sinner, E. K., Muehlenweg, B., Twellmeyer, J., Sperl, S., Wilhelm, O. G., Schmitt, M., and Magdolen, V. (2002). Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Eur. J. Biochem. 269, 184-192.
6. Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. (1998). Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. 4, 923-928.
7. Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Danø, K. et al. (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for anti-angiogenic strategies. J. Cell Biol. 152, 777-784.
8. Bajou, K. (2002). Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis. Bull. Mem. Acad. R. Med. Belg. 157, 313-318.
9. Bearz, A., Tell, G., Colombatti, A., Formisano, S., and Pucillo, C. (1998). Fibronectin binding promotes a PKC-dependent modulation of NF-kappa B in human T cells. Biochem. Biophys. Res. Commun. 243, 732-737.
10. Besta, F., Massberg, S., Brand, K., Muller, E., Page, S., Gruner, S., Lorenz, M., Sadoul, K., Kolanus, W., Lengyel, E., and Gawaz, M. (2002). Role of β3-endonexin in the regulation of NF-κB-dependent expression of urokinase-type plasminogen activator receptor. J. Cell Sci. 115, 3879-3888.
11. Blasi, F. and Carmeliet, P. (2002). uPAR: a versatile signaling orchestrator. Nature Rev. Mol. Cell Biol. 3, 932-943.
12. Bohuslav, J., Horejsi, V., Hansmann, C., Stöckl, J., Weidle, U. H., Majdic, O., Bartke, I., Knapp, W., and Stockinger, H. (1995). Urokinase plasminogen activator receptor, β2-integrin, and src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181, 1381-1390.
13. Carriero, M. V., Del Vecchio, S., Capozzoli, M., Franco, P., Fontana, L., Zannetti, A., Botti, G., D'Aiuto, G., Salvatore, M., and Stoppelli, M. P. (1999). Urokinase receptor interacts with αvβ5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59, 5307-5314.
14. Chang, A. W., Kuo, A., Barnathan, E. S., and Okada, S. (1998). Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler. Thromb. Vasc. Biol. 18, 1855-1860.
15. Chapman, H. A. and Wei, Y (2001). Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb. Haemost. 86, 124-129.
16. Chapman, H. A., Wei, Y., Simon, D. I., and Waltz, D. A. (1999). Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb. Haemost. 82, 291-297.
17. Chavakis, T., Kanse, S. M., May, A. E., and Preissner, K. T. (2002). Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation. Biochem. Soc. Trans. 30, 168-173.
18. Ciambrone, G. J. and McKeown-Longo, P. J. (1992). Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J. Biol. Chem. 267, 13617-13622.
19. Conese, M., Nykjaer, A., Petersen, C. M., Cremona, O., Pardi, R., Andreasen, P. A., Gliemann, J., Christensen, E. I., and Blasi, F. (1995). α-2 macroglobulin receptor/LDL receptor-related protein(LRP)-dependent internalization of the urokinase receptor. J. Cell Biol. 131, 1609-1622.
20. Czekay, R. P., Kuemmel, T. A., Orlando, R. A., and Farquhar, M. G. (2001). Direct binding of occupied urokinase receptor (uPA-R) to LDL receptor-related protein is required for endocytosis of uPA-R and regulation of cell surface urokinase activity. Mol. Biol. Cell 12, 1467-1479.
21. Czekay, R. P., Aertgeerts, K., Curriden, S. A., and Loskutoff , D. J. (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160, 781-791.
22. Degryse, B., Resnati, M., Rabbani, S. A., Villa, A., Fazioli, F., and Blasi, F. (1999). Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis, and cytoskeleton reorganization in rat smooth muscle cells via the urokinase receptor. Blood 94, 649-662.
23. Degryse, B., Orlando, S., Resnati, M., Rabbani, S. A., and Blasi, F. (2001). Urokinase/urokinase receptor and vitronectin/αvβ3 integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20, 2032-2043.
24. Del Rosso, M., Anichini, E., Pedersen, N., Blasi, F., Fibbi, G., Pucci, M., and Ruggiero, M. (1993). Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem. Biophys. Res. Commun. 190, 347-352.
25. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., and Loskutoff, D. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
26. Deng, G., Curriden, S. A., Hu, G., Czekay, R. P., and Loskutoff, D. J. (2001). Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J. Cell Physiol. 189, 23-33.
27. Devy, L., Blacher, S., Grignet-Debrus, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., Noel, A., Foidart, J. M. (2002). The pro- or anti-angiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16, 147-154.
28. Dumler, I., Kopmann, A., Wagner, K., Mayboroda, O. A., Jerke, U., Dietz, R., Haller, H., and Gulba, D. C. (1999a). Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J. Biol. Chem. 274, 24059-24065.
29. Dumler, I., Stepanova, V., Jerke, U., Mayboroda, O. A., Vogel, F., Bouvet, P., Tkachuk, V., Haller, H., and Gulba, D. C. (1999b). Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin. Curr. Biol. 9, 1468-1476.
30. Fazioli, F., Resnati, M., Sidenius, N., Higashimoto, Y, Appella, E., and Blasi, F. (1997). A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16, 7279-7286.
31. Fibbi, G., Ziche, M., Morbidelli, L., Magnelli, L., and Del Rosso, M. (1988). Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp. Cell Res. 179, 385-395.
32. Fischer, K., Lutz, V., Wilhelm, O., Schmitt, M., Graeff, H., Heiss, P., Nishiguchi, T., Harbeck, N., Kessler, H., Luther, T., Magdolen, V., and Reuning, U. (1998). Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett. 438, 101-105.
33. Gårdsvoll, H., Danø, K., and Ploug, M. (1999). Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J. Biol. Chem. 274, 37995-38003.
34. Germer, M., Kanse, S. M., Kirkegaard, T., Kjoller, L., Felding-Habermann, B., Goodman, S., and Preissner, K. T. (1998). Kinetic analysis of integrin-dependent cell adhesion on vitronectin - the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur. J. Biochem. 253, 669-674.
35. Ghosh, S., Brown, R., Jones, J. C. R., Ellerbroek, S. M., and Stack, S. (2000). Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by α3β1 integrin in oral keratinocytes. J. Biol. Chem. 275, 23869-23876.
36. Giancotti, F. G. and Ruoslahti, E. (1999). Integrin signaling. Science 285, 1028-1032.
37. Gudewicz, P. W. and Gilboa, N. (1987). Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. Biophys. Res. Commun. 147, 1176-1181.
38. Gutierrez, L. S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V. A., and Castellino, F. J. (2000). Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 60, 5839-5847.
39. Hapke, S., Kessler, H., Arroyo de Prada, N., Benge, A., Schmitt, M., Lengyel, E., and Reuning, U. (2001a). Integrin αvβ3/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J. Biol. Chem. 276, 26340-26348.
40. Hapke, S., Gawaz, M., Dehne, K., Köhler, J., Marshall, J. F., Graeff, H., Schmitt, M., Reuning, U., and Lengyel, E. (2001b). β(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (uPA-R) through a PEA3/ets transcriptional silencing element in the uPA-R promoter. Mol. Cell. Biol. 21, 2118-2132.
41. Hynes, R. O. (2002). A reevaluation of integrins as regulators of angiogenesis. Nature Med. 8, 918-921.
42. Irigoyen, J. P., Munoz-Canoves, P., Montero, L., Koziczak, M., and Nagamine, Y. (1999). The plasminogen activator system: biology and regulation. Cell. Mol. Life Sci. 56, 104-132.
43. Isogai, C., Laug, W. E., Shimada, H., Declerck, P. J., Stins, M. F., Durden, D. L., Erdreich-Epstein, A., and DeClerck, Y. A. (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 61, 5587-5594.
44. Jones, J. M., Cohen, R. L., and Chambers, D. A. (2002). Collagen modulates gene activation of plasminogen activator system molecules. Exp. Cell Res. 280, 244-254.
45. Kanse, S., Kost, C., Wilhelm, O., Andreasen, P. A., and Preissner, K. T. (1996). The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224, 344-353.
46. Kanse, S. M., Benzakour, O., Kanthou, C., Kost, C., Lijnen, H. R., and Preissner, K. T. (1997). Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler. Thromb. Vasc. Biol. 17, 2848-2854.
47. Khatib, A. M., Nip, J., Fallavollita, L., Lehmann, M., Jensen, G., and Brodt, P. (2001). Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor αvβ3. Int. J. Cancer 91, 300-308.
48. Kirchheimer, J. C., Wojta, J., Christ, G., and Binder, B. R. (1987). Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J. 1, 125-128.
49. Kirchheimer, J. C., Christ, G., and Binder, B. R. (1989a). Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur. J. Biochem. 181, 103-107.
50. Kirchheimer, J. C., Wojta, J., Christ, G., and Binder, B. R. (1989b). Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc. Natl. Acad. Sci. USA 86, 5424-5428.
51. Kjøller, L. and Hall, A. (2001). Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152, 1145-1157.
52. Kjøller, L., Kanse, S. M., Kirkegaard, T., Rodenburg, K. W., Rønne, E., Goodman, S. L., Preissner, K. T., Ossowski, L., and Andreasen, P. A. (1997). Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232, 420-429.
53. Knudsen, B. S., Hapel, P. C., and Nachman, R. L. (1987). Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J. Clin. Invest. 80, 1082-1089.
54. Koshelnick, Y., Ehart, M., Hufnagl, P., Heinrich, R C., and Binder, B. R. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272, 28563-28567.
55. Kusch, A., Tkachuk, S., Haller, H., Dietz, R., Gulba, D. C., Lipp, M., and Dumler, I. (2000). Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J. Biol. Chem. 275, 39466-39473.
56. Lawrence, D. A., Palaniappan, S., Stefansson, S., Olson, S. T., Francis-Chmura, A. M., Shore, J. D., and Ginsburg, D. (1997). Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J. Biol. Chem. 272, 7676-7680.
57. Lee, C. C., Shyu, K. G., Lin, S., Wang, B. W., Liu, Y C., and Chang, H. (2002). Cell adhesion regulates the plasminogen activator inhibitor-1 gene expression in anchorage-dependent cells. Biochem. Biophys. Res. Commun. 291, 185-190.
58. Loskutoff, D. J., Curriden, S. A., Hu, G., and Deng, G. (1999). Regulation of cell adhesion by PAI-1. APMIS 107, 54-61.
59. Magdolen, V., Rettenberger, P., Koppitz, M., Goretzki, L., Kessler, H., Weidle, U. H., König, B., Graeff, H., Schmitt, M., and Wilhelm, O. (1996). Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. J. Biochem. 237, 743-751.
60. May, A. E., Kanse, S. M., Lund, L. R., Gisler, R. H., Imhof, B. A., and Preissner, K. T. (1998). Urokinase receptor (CD87) regulates leukocyte recruitment via β 2 integrins in vivo. J. Exp. Med. 188, 1029-1037.
61. McMahon, G. A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M. K., Westrick, R. J., Ginsburg, D., Brooks, P. C., and Lawrence, D. A. (2001). Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968.
62. Nip, J., Rabbani, S. A., Shibata, H. R., and Brodt, P. (1995). Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J. Clin. Invest. 95, 2096-2103.
63. Nykjær, A., Petersen, C. M., Moller, B., Jensen, P. H., Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thogersen, H. C., Munch, M., Andreasen, P. A. (1992). Purified α2-macroglobulin receptor/LDL receptor-related protein binds urokinase-plasminogen activcator inhibitor type-1 complex. Evidence that the α2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J. Biol. Chem. 267, 14543-14546.
64. Nykjaer, A., Kjøller, L., Cohen, R. L., Lawrence, D. A., Garni-Wagner, B. A., Todd, R. F. 3rd, van Zonneveld, A. J., Gliemann, J., and Andreasen, P. A. (1994). Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic α2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J. Biol. Chem. 14, 25668-25676.
65. Nykjaer, A., Conese, M., Christensen, E. I., Olson, D., Cremona, O., Gliemann, J., and Blasi, F. (1997). Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16, 2610-2620.
66. Okumura, Y., Kamikubo, Y., Curriden, S. A., Wang, J., Kiwada, T., Futaki, S., Kitagawa, K., and Loskutoff, D. J. (2002). Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J. Biol. Chem. 277, 9395-9404.
67. Ossowski, L. and Aguirre-Ghiso, J. A. (2000). Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12, 613-620.
68. Ploug, M. (1998). Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPA-R domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 37, 16494-16505.
69. Pluskota, E., Soloviev, D. A., and Plow, E. F. (2003). Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin αM β2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 101, 1582-1590.
70. Qwarnström, E. E., Ostberg, C. O., Turk, G. L., Richardson, C. A., and Bomstyk, K. (1994). Fibronectin attachment activates the NF-κB p50/p65 heterodimer in fibroblasts and smooth muscle cells. J. Biol. Chem. 269, 30765-30768.
71. Rabbani, S. A., Desjardins, J., Bell, A. W., Banville, D., Mazar, A., Henkin, J., and Goltzman, D. (1990). An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. Biophys. Res. Commun. 173, 1058-1064.
72. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., and Fazioli, F. (1996). Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15, 1572-1582.
73. Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., and Blasi, F. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 99, 1359-1364.
74. Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., and Schmitt, M. (1998). Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 3, 893-906.
75. Reuning, U., Guerrini, L., Nishiguchi, T., Page, S., Seibold, H., Magdolen, V., and Schmitt, M. (1999). Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. Eur. J. Biochem. 259, 143-148.
76. Schmitt, M., Jänicke, F., Moniwa, N., Chucholowski, N., Pache, L., and Graeff, H. (1992). Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe-Seyler 373, 611-622.
77. Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Höfler, H., Jänicke, F., and Graeff, H. (1997). Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78, 285-296.
78. Schroeck, F., Arroyo de Prada, N., Sperl, S., Schmitt, M., and Magdolen, V. (2002) Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. Biol. Chem. 383, 1143-1149.
79. Schwab, W., Gavlik, J. M., Beichler, T., Funk, R. H., Albrecht, S., Magdolen, V., Luther, T., Kasper, M., and Shakibaei, M. (2001). Expression of the urokinase-type plasminogen activator receptor in human articular association with caveolin and β1-integrin. Histochem. Cell. Biol. 115, 317-323.
80. Schwartz, M. A. (2001). Integrin signaling revisited. Trends Cell Biol. 12, 466-470.
81. Seiffert, D. and Loskutoff, D. J. (1991). Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J. Biol. Chem. 266, 2824-2830.
82. Sidenius, N., Andolfo, A., Fesce, R., and Blasi, F. (2002). Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 277, 27982-27990.
83. Silvestri, I., Longanesi Cattani, I., Franco, P., Pirozzi, G., Botti, G., Stoppelli, M. P., and Carriero, M. V. (2002). Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating αvβ5 vitronectin receptor cell surface expression. Int. J. Cancer 102, 562-571.
84. Simon, D. I., Rao, N. K., Xu, H., Wei, Y., Majdic, O., Rönne, E., Kobzik, L., and Chapman, H. A. (1996). The leukocyte integrin Mac-1 (CD11b/CD18) and the urokinase receptor (uPA-R, CD87) mediate complementary functions in myelomonocytic cells. Blood 88, 3185-3194.
85. Simon, D. I., Wei, Y., Zhang, L., Rao, N. K., Xu, H., Chen, Z., Liu, Q., Rosenberg, S., and Chapman, H. A. (2000). Identification of a urokinase receptor-integrin interaction site: promiscuous regulator of integrin function. J. Biol. Chem. 275, 10228-10234.
86. Simons, K. and Toomre, D. (2000). Lipid rafts and signal transduction. Nature Rev. Mol. Cell Biol. 1, 31-39.
87. Soff, G. A., Sanderowitz, J., Gately, S., Verrusio, E., Weiss, I., Brem, S., and Kwaan, H. C. (1995). Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96, 2593-2600.
88. Stahl, A. and Mueller, B. M. (1995). The urokinase-type plasminogen activator receptor, a GPI-Iinked protein, is localized in caveolae. J. Cell Biol. 129, 335-344.
89. Stefansson, S. and Lawrence, D. A. (1996). The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 383, 441-443.
90. Stefansson, S., Muhammad, S., Cheng, X. F., Battey, F. D., Strickland, D. K., and Lawrence, D. A. (1998). Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J. Biol. Chem. 273, 6358-6366.
91. Stefansson, S., Petitclerc, E., Wong, M. K., McMahon, G. A., Brooks, P. C., and Lawrence, D. A. (2001). Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J. Biol. Chem. 276, 8135-8141.
92. Stepanova, V., Jerke, U., Sagach, V., Lindschau, C., Dietz, R., Haller, H., and Dumler, I. (2002). Urokinase-dependent human vascular smooth muscle cells adhesion requires selective vitronectin phorphorylation by ecto-protein kinase CK2. J. Biol. Chem. 277, 10265-10272.
93. Tarui, T., Mazar, A. P., Cines, D. B., and Takada, Y. (2001). Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J. Biol. Chem. 276, 3983-3990.
94. Trigwell, S., Wood, L., and Jones, P. (2000). Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck). Biochem. Biophys. Res. Commun. 278, 440-446.
95. Urtreger, A. J., Aguirre Ghiso, J. A., Werbajh, S. E., Puricelli, L. I., Muro, A. F., and Ball De Kier Joffe, E. (1999). Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. Int. J. Cancer 82, 748-753.
96. Van der Pluijm, G., Sijmons, B., Vloedgraven, H., van der Bent, C., Drijfhout, J. W., Verheijen, J., Quax, P, Karperien, M., Papapoulos, S., and Lowik, C. (2001). Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol. 159, 971-982.
97. Vasalli, J. D., Baccino, D., and Belin, D. (1985). A cellular binding site for the Mr 55000 form of the human plasminogen activator urokinase. J. Cell Biol. 100, 86-92.
98. Waltz, D. A., Natkin, L. R., Fujita, R. M., Wei, Y., and Chapman, H. A. (1997). Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100, 58-67.
99. Waltz, D. A., Fujita, R. M., Yang, X., Natkin, L., Zhuo, S., Gerard, C. J., Rosenberg, S., and Chapman, H. A. (2000). Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am. J. Respir. Cell Mol. Biol. 22, 316-322.
100. Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S., and Chapman, H. A. (1994). Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269, 32380-32388.
101. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., and Chapman, H. A. (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
102. Wei, Y., Yang, X., Liu, Q., Wilkins, J. A., and Chapman, H. A. (1999). A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144, 1285-1294.
103. Wei, Y., Eble, J. A., Wang, Z., Kreidberg, J. A., and Chapman, H. A. (2001). Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol. Biol. Cell 12, 2975-2986.
104. Wilcox-Adelman, S. A., Wilkins-Port C. E., and McKeown-Longo, P. J. (2000). Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors. Cell Adhes. Commun. 7, 477-490.
105. Xue, W., Mizukami, I., Todd, R. F. 3rd, and Petty, H. R. (1997). Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: dependence on ECM components. Cancer Res. 57, 1682-1689.
106. Yebra, M., Filardo, E. J., Bayna, E. M., Kawahara, E., Becker, J. C., and Cheresh, D. A. (1995). Induction of carcinoma cell migration on vitronectin by NF-κB-dependent gene expression. Mol. Biol. Cell 6, 841-850.
107. Yebra, M., Parry, G. C. N., Stromblad, S., Mackman, N., Rosenberg, S., Mueller, B. M., and Cheresh, D. A. (1996). Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J. Biol. Chem. 271, 29393-29399.
108. Yebra, M., Goretzki, L., Pfeifer, M., and Mueller, B. M. (1999). Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp. Cell Res. 250, 231-240.